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Abstract: We assess the influence of co-occurring psychiatric disorders on retention in 189 
opioid dependent patients in a methadone maintenance treatment (MMT) and determine the 
incidence of psychiatric co-morbidity during an 18-month follow-up period. About 68.5 % 
were retained in the MMT. Neither co-occurring mental disorders (chi-square = 0.303,  
df = 1, p = 0.622) nor methadone doses [85 (88.9) vs. 79.2 (85) mg/day, p = 0.672] were 
related to retention. In the follow-up period 19 new diagnoses were made, mainly major 
depression and antisocial and borderline personality disorders. Co-occurring psychiatric 
disorders should be assessed during MMT follow-up. 
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1. Introduction 
 
In the management of heroin dependent subjects methadone maintenance treatment (MMT) 
programs are effective in reducing heroin use, crime related to drug use, HIV risk behaviors, overdose 
mortality [1-3] and improving quality of life [4,5]. Effectiveness is related to the effect of methadone 
on retaining patients in the program. Research into the factors related to retention in MMT is an 
important issue in order to improve the effectiveness of MMT.  
Previous studies suggest that the patient must stay for at least one year in the MMT for the 
treatment to be effective [6,7] although longer treatment is recommended. In different studies, the  
1-year retention rate ranges between 25% to 82% [6,8-13]. Factors associated with retention rate are 
methadone dosage [2,14], differences between treatment settings [15], severity of drug use at the time 
of enrolment in the program [16] and age at time of MMT entrance [17]. The influence of co-occurring 
mental disorders other than substance abuse has also been studied, although results remain 
controversial [11,13,15,18]. This could be mainly related to the difficulties in diagnosing co-occurring 
disorders in substance users [19,20] and to the fact that in previous studies the patients were only 
assessed at the time of admission into MMT and therefore the role of new non-substance use 
psychiatric diagnosis during the follow-up period was not considered. 
A prospective follow-up study of opioid dependent patients included in the MMT [21] was carried 
out with the following objectives: (1) to assess the influence of co-occurring disorders on retention in 
the MMT program and (2) to determine the incidence of co-occurring disorders during an 18-month 
follow-up. 
 
2. Methods 
 
2.1. Sample 
 
The study participants were 189 opioid dependent patients (77% male, mean age 34 ± 7.5 years) 
consecutively admitted to a MMT in Barcelona, Spain, and followed up to 18 months.  
 
2.2. Procedure 
 
In the baseline visit, after full explanation of the purposes of the study, written informed consent 
was obtained and patients were assessed with the PRISM-IV and a close-ended questionnaire  
(see other variables). At follow-up (18 months) patients were reassessed with the same measures. The 
study protocol was approved by the institutional review board. 
 
2.3. Methadone Maintenance Treatment 
 
The MMT provided at the Drug Abuse Out-patient Centre (CAS-BARCELONETA) is a  
low-threshold MMT, that is to say such program is not abstinence oriented. The only requirement for 
inclusion in the program is a definitive diagnosis of opioid dependence according to DSM-IV criteria. 
Forced discharge only occurs for aggressive behavior and drug trafficking in the centre. There is a high 
Int. J. Environ. Res. Public Health 2009, 6         
 
 
2824 
dose policy (no upper limit) and no restriction on long-term treatment (no time limit). The induction 
period on MMT lasts about 1–2 months until the stable maintenance doses is achieved. Urine 
toxicology screens are carried out randomly once a week under supervision. Methadone is dispensed to 
patients daily on the form of syrup with orange juice and has to be ingested in the presence of a nurse. 
Take-home methadone doses are provided when weekly urine screening tests are repeatedly clean  
(at least for a period of one month). Take-home privileges are revoked in response to positive urine 
tests results, and patients are referred to the clinicians to assess a possible increase in methadone doses. 
In addition to methadone and urine drug screen, individual counseling is the major therapeutic vehicle 
and frequency varies depending upon the stage of treatment and patient needs. Counseling focused on 
encouraging reduced drug use and helping patients to cope with problems (either through direct 
counseling or referral to other services) that made them more vulnerable to continued drug use  
is provided. 
 
2.4. Current Co-Occurring Diagnoses 
 
Diagnoses of current substance use disorder (SUD) and co-occurring mental disorders, were carried 
out according to DSM-IV criteria and using the Spanish version of the Psychiatric Research Interview 
for Substance and Mental Disorders (PRISM-IV) [22], administered by two trained psychologist 
researchers with clinical experience with patients with substance abuse or mental disorders. The 
PRISM-IV has shown a good test-retest reliability [23] and validity [22] in substance abusers. 
 
Figure 1. Situation of the 189 opioid dependent patients admitted to a MMT at 18 months 
follow-up. 
 
* Co-occurring disorders: co-occurring substance use [abuse or dependence] and mental disorders. 
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2.5. Other Variables 
 
Baseline patient’s sociodemographic characteristics (including employment and legal status), and 
drug use and sexual risk behaviors, substance use variables, and infection by HIV and hepatitis C virus 
were collected with a close-ended questionnaire [21]. At follow-up, the questionnaire included data on 
MMT provided (methadone dose received at 18 months). In the patients not retained in the program, 
data on the last methadone dose administered before interruption of MMT was used.  
 
2.6. Statistical Analysis 
 
All statistical analyses were carried out with the SPSS statistical software package [SPSS V14; 
Chicago, IL, USA]. Retention in the MMT was defined as remaining in the same MMT program, and 
after stable doses of methadone was reached. The presence of co-occurring mental disorders at 
baseline between retained and non-retained patients was compared with Pearson's chi-square test. 
Fisher's exact test was used when one or more cells of the contingency tables had expected counts of 
less than five. 
To determine which variables were associated with MMT retention, we compared retained versus 
non-retained patients in the following baseline variables: sociodemographic (sex, age, education level, 
employment, legal status); psychopathological (co-occurring mental disorders [yes/no]); use of the 
following substances during the last month: alcohol, sedatives, cocaine, cannabis, opiates other than 
heroine; SUD diagnoses (yes/no) of the following substances: alcohol, sedatives, cocaine, cannabis, 
opiates other than heroine; VIH/Hepatitis C risk-related variables: i.v. route use, sharing injection 
material, sexual risk behavior (yes/no for always using condoms); presence or absence of HIV-Ab 
and/or HCV-Ab; and methadone dose. Comparisons were made by means of Pearson's chi-square test 
or Fisher's
 
exact test (for categorical variables) and Student s´ t-test (for continuous variables). A 
logistic regression analysis with retention as the dependent variable and those of the former variables 
that showed a p-value of less than 0.25 in the univariate analyses: sex, age, educational level, and 
current diagnosis of cocaine and opiates other than heroin dependence as independent variables was 
done. The goodness-of-fit of the model was assessed by the Hosmer–Lemeshow test. 
To assess the incidence of co-occurring disorders during the follow-up, the cumulative incidence 
(ratio of incident cases divided by those subjects without co-occurring disorders at baseline) and the 
incidence rate (ratio of new diagnoses divided by total time of follow-up) of retained cases  
were calculated. 
Exact 95 % confidence intervals for the incidence rate based on the Poisson distribution  
were calculated. 
 
3. Results 
 
Table 1 shows a summary of the baseline characteristics of the sample differentiating among those 
128 (67.7%) cases with only a current SUD diagnosis and 61 (32.3%) with a current co-occuring 
mental disorders. Anxiety disorders were the most frequent Axis-I diagnoses, followed by mood 
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disorders, and psychotic disorders. More than 20% of the sample fulfilled the criteria for antisocial or 
borderline personality disorder.  
 
Table 1. Differences between patients with/without co-occurring disorders at baseline. 
 
Variable 
Co-occurring 
disorders 
N = 61 (%) 
Only SUD 
N = 128 (%) 
 
2 or t 
 
df 
 
p 
Women 20 (32.8) 24 (18.8) 2 = 4.557 1 0.043 
Age, years, mean (SD) 33.34 (8.8) 34.1(6.8) t = –0.637 187 0.525 
Marital status 
 Single 
 Currently married 
 Separated/divorced 
 
42 (68.9) 
12 (19.7) 
7 (11.5) 
 
60 (46.9) 
45 (35.2) 
23 (18) 
 
 
2 = 8.079 
 
 
2 
 
 
0.018 
Education level 
 Primary School 
 Secondary School 
 University 
 
29 (47.5) 
20 (32.8) 
12 (19.7) 
 
47 (36.7) 
50 (39.1) 
31 (24.2) 
 
 
2 = 2.018 
 
 
2 
 
 
0.365 
 Any month employed last six months 26 (42.6) 87 (68) 2 = 11.039 1 0.001 
Legal status 
 Any detention last six months 
 Any imprisonment last 6 months 
 
20 (32.8) 
7 (11.5) 
 
24 (18.8) 
11 (8.6) 
 
2 = 4.557 
2 = 0.398 
 
1 
1 
 
0.043 
0.598 
Serological status 
 HIV—Ab positive 
 HCV—Ab positive 
 
18 (29.5) 
39 (63.9) 
 
27 (21.8) 
58 (48.7) 
 
2 = 1.329 
2 = 3.747 
 
1 
1 
 
0.276 
0.059 
HIV current risk behaviors last six 
months 
 Any i.v. drug use 
 Any sexual risk behavior  
 
38 (62.3) 
30 (49.2) 
 
57 (44.5) 
73 (57) 
 
2 = 5.215 
2 = 1.027 
 
1 
1 
 
0.029 
0.350 
Drug use last 30 days 
 Alcohol 
 Cocaine 
 Sedatives 
 Other opiates 
 Cannabis 
 
5 (8.2) 
10 (16.4) 
15 (24.6) 
9 (14.8) 
18 (29.5) 
 
23 (18) 
15 (11.7) 
16 (12.5) 
21 (16.4) 
35 (27.3) 
 
2 = 3.127 
2 = 2.402 
2 = 4.423 
2 = 0.084 
2 = 0.586 
 
2 
2 
2 
2 
2 
 
0.209 
0.301 
0.110 
0.834 
0.746 
Cocaine route use 
 Snorted/Smoked 
 Injected 
 
13 (38.2) 
21 (61.8) 
 
27 (50) 
27 (50) 
 
2 = 1.165 
 
1 
 
0.380 
Heroine route use 
 Smoked/Inhaled 
 Snorted 
 Injected 
 
12 (18.7) 
11 (18) 
38 (62.3) 
 
37 (28.9) 
33 (25.8) 
58 (45.3) 
 
 
2 = 4.770 
 
 
1 
 
 
0.092 
 
Abuse or dependence diagnoses 
 Alcohol 
 Other opiates 
 Cocaine 
 Sedatives 
 Cannabis 
 Stimulants 
 
6 (9.8) 
4 (6.6) 
25 (41) 
11 (18) 
17 (27.9) 
2 (3.3) 
 
12 (9.4) 
9 (7) 
43 (33.6) 
18 (14.1) 
20 (15.6) 
2 (1.6) 
 
2 = 0.010 
2 = 0.014 
2 = 0.979 
2 = 0.501 
2 = 3.934 
2 = 0.587 
 
1 
1 
1 
1 
1 
1 
 
1 
1 
0.335 
0.520 
0.053 
0.596 
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Table 1. Cont. 
Non-SUD co-occurring diagnoses 
 Only Axis I 
 Only Axis II 
 Both Axis I + II 
 
32 (52.5) 
22 (36.1) 
7 (11.5) 
 
- 
- 
- 
   
 Major depression 
 Induced depression 
 Schizophrenia 
 Panic w/without agoraphobia 
 Social phobia 
 Simple phobia 
 Post traumatic stress 
 Obsessive compulsive 
 Bulimia 
9 (14.8) 
5 (8.2) 
5 (8.2) 
12 (19.7) 
10 (16.4) 
8 (13.1) 
- 
4 (6.6) 
1 (1.6) 
    
Antisocial Personality Disorder 
Borderline Personality Disorder 
16 (26.2) 
13 (21.3) 
    
Co-occurring diagnoses: co-occurring substance use [abuse or dependence] and mental disorders; Only 
SUD: Only substance use disorders. 
 
The situation of patients during the 18-month follow-up period is shown in Figure 1. Sixty-three of 
the 189 patients dropped out the study because of death, imprisonment or MMT discontinuation. 
Therefore, a total of 126 patients were followed, with a retention rate of 68.5%. Some baseline 
differences between the 126 patients who continued in the MMT and the 63 patients who dropped out 
were found. Subjects that dropped out used more cocaine, (57.1% vs. 38.1%; chi square = 7.510,  
df = 2, p = 0.023), reported more i.v. route (65.1% vs. 42.9%; chi square = 8.297, dfl = 1, p = 0.005) 
and less sexual risk behaviors (36.5% vs. 63.5%; chi square = 12.333, dfl = 1, p = 0.001) during last 30 
days before starting in the MMT. Furthermore, subjects that dropped out had more past  
(68.3% vs. 51.6%; chi square = 4.764, df = 1, p = 0.030) and current (44.4% vs. 27%;  
chi square = 5.809, df = 1, p = 0.021) cocaine dependence diagnoses than subjects who continued in 
the MMT.  
Twenty-nine patients were not available for reassessment at follow-up, even if still in MMT. 
Baseline differences were found respect to those 97 patients retained in MMT and reassessed at follow 
up. The 29 who did not accepted to be reassessed used more the i.v. route (65.5% vs. 36.1%;  
chi square = 7.898, df = 1, p = 0.006) and higher alcohol (17.2% vs. 13.4%; chi square = 7.236, df = 2, 
p = 0.027) and cocaine (58.6% vs. 19.6%; chi square = 17.731 df = 2, p < 0.001) in the 30 days before 
entering MMT. Furthermore, the 29 patients had more antisocial personality disorder diagnoses 
(17.2% vs. 4.1%; chi square = 5.792, df = 1, p < 0.030) (data not shown). 
Of the 61 patients with co-occurring mental disorders at baseline, 39 (63.9 %) were retained in the 
MMT programme and 22 (36.1 %) were lost to follow-up, whereas from the 128 without co-occurring 
mental disorders, 87 (68%) patients were retained (chi-square = 0.303, df = 1, p = 0.622). No 
difference in baseline characteristics were observed between the patients retained in MMT and 
available for the reassessment at time of follow-up (n = 97) and those retained but not available for the 
reassessment (n = 29). The difference between methadone dosage of those patients retained in the 
MMT and last dose administered in those who dropped out was not statistically significant  
[85.5 (88.9) vs. 79.2 (85) mg/day, p = 0.672]. None of the variables included in the multivariate model 
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were significant predictors of treatment retention, although being male (OR: 2.59, 95% CI: 0.98–6.84;  
p = 0.055) and lower educational level (OR: 2.65, 96% CI: 0.98–7.13; p = 0.054) were nearly 
significant predictors of non-retention. The p-value of the Hosmer-Lemeshow tests was 0.47 indicating 
that the model fit was satisfactory. 
A total of 107 patients were available for the assessment of co-occurring mental disorders at  
follow-up. Co-occurring disorders were established in 29 subjects. When patients with (n = 29) and 
without (n = 78) co-occurring disorders were compared, those with co-occurring disorders had worked 
fewer months before admission in the MMT (41.4% vs. 69.2%, p = 0.013) and before reassessment at 
follow-up (24.1% vs. 50%, p = 0.027), showed higher percentage of current alcohol abuse diagnoses 
(13.8% vs. 1.3%, p = 0.019) and had received more psychiatric treatment (44.8% vs. 19.2%,  
p = 0.012). 
In 10 of the 107 patients, at least one new co-occurring disorder was diagnosed, with a total of 19 
diagnoses. Sixty percent of these 10 patients were men, with a mean age of 31.60 (5.73) years. The 
cumulative incidence of co-occurring disorders was 13% (95% CI 6.4% to 22.5%). The cumulative 
incidence in the 97 patients retained in the MMT program and reassessed was 11.43 % (95% CI 5.07% 
to 21.28%) compared with 28.6% (95% CI 3.7% to 71%) in 10 patients reassessed but not retained in 
the MMT program. 
Of the 19 new diagnoses, 16 were made in the 97 patients retained in MMT and reassessed, and 3 in 
the subsample of 10 patients not retained but reassessed. The incidence rate of co-occurring disorders 
at follow-up was 0.11 diagnoses per year (95% CI 0.06 to 0.18) in patients retained in MMT and 0.20 
(95% CI 0.04 to 0.58) in those not retained. Nine new Axis I diagnoses were done: major depression 
(five diagnoses), anxiety disorders (one panic disorder and one specific phobia) and psychotic disorder 
(one induced and one primary). Regarding Axis II disorders, 10 new diagnoses had been made of 
personality disorders (five antisocial personality disorder [APD] and five borderline personality 
disorder [BPD]); see Table 2 for more details. 
 
Table 2. Co-occurring disorders incidence in a cohort of 107 patients reassessed at  
18 months. 
 Co-occurring disorders 
Disorders at baseline Baseline Follow-up 
  Axis I Axis II Axis I & II 
Only SUD  77 1 Induced 
Psychosis
a
 
1 Simple Phobia 
1 Schizophrenia 
1 APD & BPD
a,b
 
1 APD 
2 BPD 
 
Non SUD co-occurring diagnoses 30    
Axis I 19    
 Major Depression 7 
 1 BPD 
1 Induced 
Depression & 
BPD
b
 
 Induced Depression 1    
 Schizophrenia 2    
 Induced Psychosis -    
 Panic w/without Agoraphobia 9 3 Major Depression   
 Social Phobia 6  2 APD  
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Table 2. Cont. 
 Simple Phobia 4    
 Obsessive Compulsive 3  1 APD  
Axis II 8    
 Antisocial Personality 5    
 Borderline Personality 6    
Axis I & II 3    
 Social Phobia, Induced Depression 
& BPD 
1 1 Major 
Depression 
  
 Panic with/without Agoraphobia & 
BPD 
1 1 Major 
Depression 
  
 Panic with/without Agoraphobia & 
APD 
1 
   
a 
Patients from the subsample of 10 patients not retained but assessed; 
b 
Both diagnoses in single patient; 
APD: Antisocial personality disorder; BPD: Borderline personality disorder. 
 
4. Discussion  
 
In this study, the overall cumulative incidence of co-occurring disorders in methadone-treated 
opioid dependent patients followed-up for 18 months was 13%. Major depression and antisocial and 
borderline personality disorders were the most common new diagnoses. The cumulative incidence, 
although not statistically significant, was lower in patients retained in MMT than those not retained. 
Moreover, co-occurring disorders at the time of inclusion in the MMT was not related to retention  
in treatment.  
Major depression has been the main incident Axis I diagnoses. Interestingly, all those patients had 
been diagnosed with an anxiety disorder at baseline. Our results are similar to those obtained by others 
at 12 months follow-up after discharge of inpatient detoxification treatment using similar  
methodology [20], but differ from those of Grant et al. [24], suggesting that anxiety disorders at 
baseline more often predicted incidence of anxiety disorders rather than mood disorders in the general 
population. The establishment of new personality disorders was indeed quite surprising, since a 
personality disorder implies a pattern of behaviors developing through one’s adult life, beginning in 
the early adulthood. Such result could be explained by the fact that at baseline patients were diagnosed 
just at admission of MMT and it was more difficult to differentiate personality than substance related 
symptoms. In agreement with other authors [13,25], we consider that the diagnoses of personality 
disorders should be done once the patients have become clinically stabilized. 
Although in the univariate analysis, cocaine use as IV use at entrance, was a predictor of drop-out 
of treatment in agreement with previous studies[26], in the multivariate regression analysis, no 
significant relationship was proven between these variables and the retention in MMT. Nor did we find 
other significant predictor of retention in MMT, although statistical significance was almost reached 
for two variables (gender and education level). It seems that patients with a lower educational level 
might need some specific treatment approaches, such as mapping-enhanced counseling to improve 
treatment outcomes. Previous studies [27,28] found controversial results regarding education level and 
MMT retention. We did not observe a relationship between methadone dose and retention in treatment, 
probably because mean dose of methadone administered (near 80 mg/day in both groups) was in the 
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recommended range [14]. Psychiatric comorbidity did not show any influence on patient’s retention in 
MMT, as previously described by other authors[11,13,18]. 
Some study limitations should be mentioned. Firstly, the lack of the assessment of psychosocial 
interventions received during the treatment, and secondly, the fact that co-occurring mental disorders 
were only evaluated in a small percentage of subjects not retained in the MMT.  
In summary, the present study shows a relatively high cumulative incidence of co-occurring 
diagnoses (mainly major depression) among opioid dependent patients available at follow-up. 
Furthermore, the unexpected rate of new personality disorder diagnoses established in MMT retained 
patients enhances the relevance of careful detection of co-occurring mental disorders not only at the 
time admission to the treatment, but also throughout the whole program. 
 
Funding and Support 
 
Conflicts of interest: Not declared. This study was supported by grants from ―Plan Nacional sobre 
Drogas‖ (2SI/01/07) and ―Fondo de Investigación Sanitaria‖ (FIS) (G03/005 and PI052086),  
Madrid, Spain. 
 
Acknowledgements 
 
The authors are grateful to the nurses of the primary drug treatment centers (CAS Creu Roja, CAS 
Sants and CAS Barceloneta) for their participation in the recruitment of subjects, Klaus Langhor, MD, 
and Albert Sanchez-Niubó for their contribution in the statistical analysis, and Marta Pulido, MD, for 
editing the manuscript and editorial assistance. 
 
References 
 
1.   Marsch, L.A. The efficacy of methadone maintenance interventions in reducing illicit opiate use, 
HIV risk behavior and criminality: a meta-analysis. Addiction 1998, 93, 515-532. 
2.   Amato, L.; Davoli, M.; Perucci, C.A.; Ferri, M.; Faggiano, F.; Mattick, R.P. An overview of 
systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to 
inform clinical practice and research. J. Subst. Abuse Treat. 2005, 28, 321-329. 
3.   Brugal, M.T.; Domingo-Salvany, A.; Puig, R.; Barrio, G.; Garcia, D.O.; de la Fuente L. 
Evaluating the impact of methadone maintenance programmes on mortality due to overdose and 
aids in a cohort of heroin users in Spain. Addiction 2005, 100, 981-989. 
4.   Torrens, M.; San, L.; Martinez, A.; Castillo, C.; Domingo-Salvany, A.; Alonso, J. Use of the 
Nottingham Health Profile for measuring health status of patients in methadone maintenance 
treatment. Addiction 1997, 92, 707-716. 
5.   Torrens, M.; Domingo-Salvany, A.; Alonso, J.; Castillo, C.; San, L. Methadone and quality of 
life. Lancet 1999, 353, 1101. 
6.   Friedmann, P.D.; Lemon, S.C.; Anderson, B.J.; Stein, M.D. Predictors of follow-up health status 
in the Drug Abuse Treatment Outcome Study (DATOS). Drug Alcohol Depend. 2003, 69,  
243-251. 
Int. J. Environ. Res. Public Health 2009, 6         
 
 
2831 
7.   Simpson, D.; Sells, S. Effectiveness of treatment for drug abuse: an overwiew of the DARP 
research program. Adv. Alcohol Subst. Abuse 1982, 2, 7-29. 
8.   Chatham, L.R.; Hiller, M.L.; Rowan-Szal, G.A.; Joe, G.W.; Simpson, D.D. Gender differences at 
admission and follow-up in a sample of methadone maintenance clients. Subst. Use Misuse 1999, 
34, 1137-1165. 
9.   Gossop, M.; Stewart, D.; Browne, N.; Marsden, J. Methadone treatment for opiate dependent 
patients in general practice and specialist clinic settings: Outcomes at 2-year follow-up. J. Subst. 
Abuse Treat. 2003, 24, 313-321. 
10.  Peles, E.; Schreiber, S.; Adelson, M. Factors predicting retention in treatment: 10-year experience 
of a methadone maintenance treatment (MMT) clinic in Israel. Drug Alcohol Depend. 2006, 82, 
211-217. 
11.  Gelkopf, M.; Weizman, T.; Melamed, Y.; Adelson, M.; Bleich, A. Does psychiatric comorbidity 
affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure 
and infectious diseases in an Israeli methadone maintenance clinic. Isr. J. Psychiatry Relat. Sci. 
2006, 43, 126-136. 
12.  Teesson, M.; Ross, J.; Darke, S.; Lynskey, M.; Ali, R.; Ritter, A.; Cooke, R. One year outcomes 
for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Drug 
Alcohol Depend. 2006, 83, 174-180. 
13.  Cacciola, J.S.; Alterman, A.I.; Rutherford, M.J.; McKay, J.R.; Mulvaney, F.D. The relationship of 
psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug Alcohol 
Depend. 2001, 61, 271-280. 
14.  Farre, M.; Mas, A.; Torrens, M.; Moreno, V.; Cami, J. Retention rate and illicit opioid use during 
methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend. 2002, 65, 283-290. 
15.  Broome, K.M.; Flynnn, P.M.; Simpson, D.D. Psychiatric comorbidity measures as predictors of 
retention in drug abuse treatment programs. Health Serv. Res. 1999, 34, 791-806. 
16.  Morral, A.R.; Belding, M.A.; Iguchi, M.Y. Identifying methadone maintenance clients at risk for 
poor treatment response: pretreatment and early progress indicators. Drug Alcohol Depend. 1999, 
55, 25-33. 
17.  Torrens, M.; Castillo, C.; Perez-Sola, V. Retention in a low-threshold methadone maintenance 
program. Drug Alcohol Depend. 1996, 41, 55-59. 
18.  Verthein, U.; Degkwitz, P.; Haasen, C.; Krausz, M. Significance of comorbidity for the long-term 
course of opiate dependence. Eur. Addict. Res. 2005, 11, 15-21. 
19.  Schuckit, M.A. Comorbidity between substance use disorders and psychiatric conditions. 
Addiction 2006, 101, 76-88. 
20.  Nunes, E.V.; Rounsaville, B.J. Comorbidity of substance use with depression and other mental 
disorders: from Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) 
to DSM-V. Addiction 2006, 101, 89-96. 
21.  Astals, M.; Domingo-Salvany, A.; Castillo-Buenaventura, C.; Tato, J.; Vazquez, J.M.; Martin-
Santos, R.; Torrens, M. Impact of substance dependence and dual diagnosis on the quality of life 
of heroin users seeking treatment. Subst. Use Misuse 2008, 43, 612-632. 
Int. J. Environ. Res. Public Health 2009, 6         
 
 
2832 
22.  Torrens, M.; Serrano, D.; Astals, M.; Perez-Dominguez, G.; Martin-Santos, R. Diagnosing 
comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the 
Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical 
Interview for DSM-IV. Am. J. Psychiatry 2004, 161, 1231-1237. 
23.  Hasin, D.; Samet, S.; Nunes, E.; Meydan, J.; Matseoane, K.; Waxman, R. Diagnosis of comorbid 
psychiatric disorders in substance users assessed with the Psychiatric Research Interview for 
Substance and Mental Disorders for DSM-IV. Am. J. Psychiatry 2006, 163, 689-696. 
24.  Grant, B.F.; Goldstein, R.B.; Chou, S.P.; Huang, B.; Stinson, F.S.; Dawson, D.A.; Saha, T.D.; 
Smith, S.M.; Pulay, A.J.; Pickering, R.P.; Ruan, W.J.; Compton, W.M. Sociodemographic and 
psychopathologic predictors of first incidence of DSM-IV substance use, mood and anxiety 
disorders: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related 
Conditions. Mol. Psychiatry 2008. 
25.  Verheul, R. Co-morbidity of personality disorders in individuals with substance use disorders. 
Eur. Psychiatry 2001, 16, 274-282. 
26.  Darke, S.; Wodak, A.; Hall, W.; Heather, N.; Ward, J. Prevalence and predictors of 
psychopathology among opioid users. Br. J. Addict. 1992, 87, 771-776. 
27.  Pitre, U.; Dansereau, D.F.; Joe, G.W. Client education levels and the effectiveness of node-link 
maps. J. Addict. Dis. 1996, 15, 27-44. 
28.  Szapocznik, J.; Ladner, R. Factors related to successful retention in methadone maintenance: a 
review. Int. J. Addict. 1977, 12, 1067-1085. 
 
© 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. 
This article is an open-access article distributed under the terms and conditions of the Creative 
Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). 
